[HTML][HTML] A randomized non-comparative phase II study of anti-programmed cell death-ligand 1 atezolizumab or chemotherapy as second-line therapy in patients with …
JL Pujol, L Greillier, C Audigier-Valette… - Journal of Thoracic …, 2019 - Elsevier
Introduction This randomized phase II trial aimed at evaluating the engineered programmed
cell death ligand 1 (PD-L1) antibody atezolizumab in SCLC progressing after first-line …
cell death ligand 1 (PD-L1) antibody atezolizumab in SCLC progressing after first-line …
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With …
JL Pujol, L Greillier, C Audigier-Valette… - Journal of Thoracic …, 2019 - jto.org
Introduction This randomized phase II trial aimed at evaluating the engineered programmed
cell death ligand 1 (PD-L1) antibody atezolizumab in SCLC progressing after first-line …
cell death ligand 1 (PD-L1) antibody atezolizumab in SCLC progressing after first-line …
[引用][C] A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients …
JL Pujol, L Greillier, C Audigier-Valette… - Journal of Thoracic …, 2019 - inria.hal.science
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1
Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung …
Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung …
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With …
JL Pujol, L Greillier… - Journal of thoracic …, 2019 - pubmed.ncbi.nlm.nih.gov
Introduction This randomized phase II trial aimed at evaluating the engineered programmed
cell death ligand 1 (PD-L1) antibody atezolizumab in SCLC progressing after first-line …
cell death ligand 1 (PD-L1) antibody atezolizumab in SCLC progressing after first-line …
[PDF][PDF] A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients …
JL Pujol, L Greillier, C Audigier-Valette… - Journal of Thoracic …, 2019 - hal.science
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1
Atezolizumab or Chemotherapy as Second-Line T Page 1 HAL Id: hal-02570679 https://hal.science/hal-02570679 …
Atezolizumab or Chemotherapy as Second-Line T Page 1 HAL Id: hal-02570679 https://hal.science/hal-02570679 …
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With …
JL Pujol, L Greillier, C Audigier-Valette… - Journal of Thoracic …, 2019 - europepmc.org
Methods Patients were randomized 2: 1 to atezolizumab (1200 mg intravenously every 3
weeks) until progression or unacceptable toxicity, or conventional chemotherapy (up to 6 …
weeks) until progression or unacceptable toxicity, or conventional chemotherapy (up to 6 …
[PDF][PDF] A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients …
JL Pujol, L Greillier, C Audigier-Valette, D Moro-Sibilot… - 2019 - hal.science
Introduction: This randomized phase 2 trial aimed at evaluating the engineered programmed
cell death-ligand 1 (PD-L1) antibody atezolizumab in small cell lung cancer progressing …
cell death-ligand 1 (PD-L1) antibody atezolizumab in small cell lung cancer progressing …